1. Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors
   Khayal Gasimli et al, 2023, Cancers CrossRef
2. Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models
   Xin-Mo Liu et al, 2023, World Journal of Gastrointestinal Oncology CrossRef
3. A novel synthesized prodrug of gemcitabine based on oxygen-free radical sensitivity inhibited the growth of lung cancer cells
   Xinlu Chai et al, 2023, The Journal of Biomedical Research CrossRef
4. BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas
   Victor Moreno et al, 2023, Nature Communications CrossRef
5. Epigenetics of cisplatin resistance
   Anne-Marie Baird et al, 2023, Epigenetic Cancer Therapy CrossRef
6. A Systematic Review of Progress toward Unlocking the Power of Epigenetics in NSCLC: Latest Updates and Perspectives
   Anetta Sulewska et al, 2023, Cells CrossRef
7. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
   Kenneth K. W. To et al, 2023, Molecules CrossRef
8. Pathogenic role of super-enhancers as potential therapeutic targets in lung cancer
   Zhiyuan Yao et al, 2024, Frontiers in Pharmacology CrossRef
9. Bromodomain‐containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death‐ligand 1 expression
   Jiajie Ren, 2024, Basic & Clinical Pharmacology & Toxicology CrossRef